Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers

Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers Hirofumi Yasue, Yuji Mizuno, Eisaku Harada, Teruhiko Itoh, Hitoshi Nakagawa, Masafumi Nakayama, Hisao Ogawa, Shinji Tayama, Takasi Honda, Seiji Hokimoto...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2008-05, Vol.51 (18), p.1742-1748
Hauptverfasser:	Yasue, Hirofumi, MD, Mizuno, Yuji, MD, Harada, Eisaku, MD, Itoh, Teruhiko, MD, Nakagawa, Hitoshi, MD, Nakayama, Masafumi, MD, Ogawa, Hisao, MD, Tayama, Shinji, MD, Honda, Takasi, MD, Hokimoto, Seiji, MD, Ohshima, Shuichi, MD, Hokamura, Youichi, MD, Kugiyama, Kiyotaka, MD, Horie, Minoru, MD, Yoshimura, Michihiro, MD, Harada, Masaki, MD, Uemura, Shiroh, MD, Saito, Yoshihiko, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylcholine - pharmacology Adult Aged Aged, 80 and over Angina pectoris Biological and medical sciences Calcium Channel Blockers - therapeutic use Cardiology Cardiology. Vascular system Cardiovascular Cholesterol Coronary Angiography Coronary heart disease Coronary Vasospasm - drug therapy Coronary Vasospasm - physiopathology Coronary vessels Coronary Vessels - drug effects Coronary Vessels - pathology Endothelium - drug effects Endothelium - physiopathology Fatty Acids, Monounsaturated - therapeutic use Female Heart Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Indoles - therapeutic use Internal Medicine Male Medical sciences Middle Aged Nitric Oxide Older people Prospective Studies Risk Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers Hirofumi Yasue, Yuji Mizuno, Eisaku Harada, Teruhiko Itoh, Hitoshi Nakagawa, Masafumi Nakayama, Hisao Ogawa, Shinji Tayama, Takasi Honda, Seiji Hokimoto, Shuichi Ohshima, Youichi Hokamura, Kiyotaka Kugiyama, Minoru Horie, Michihiro Yoshimura, Masaki Harada, Shiroh Uemura, Yoshihiko Saito, for the SCAST (Statin and Coronary Artery Spasm Trial) Investigators Sixty-four patients in whom coronary spasm was induced by intracoronary injection of acetylcholine were randomly assigned to fluvastatin 30 mg/day plus the conventional therapy (31 patients, statin group) or the conventional therapy (33 patients, nonstatin group) for 6 months of treatment. There was a significant reduction in the number of patients with acetylcholine-induced coronary spasm in the statin group as compared with the nonstatin group after 6 months of treatment (51.6% vs. 21.2%, p = 0.0231). Thus, a statin (fluvastatin) may possibly be used as a novel drug for the treatment of coronary spasm.
ISSN:	0735-1097 1558-3597
DOI:	10.1016/j.jacc.2007.12.049